發(fā)布時(shí)間：2018-05-08 16:19

  本文選題：唑來膦酸 + PKP�。� 參考：《蘇州大學(xué)》2015年碩士論文

【摘要】：目的：探討唑來膦酸(密固達(dá))聯(lián)合PKP技術(shù)治療老年椎體壓縮性骨折的臨床療效。方法：回顧性分析我科于2012-2014年收治老年椎體壓縮性骨折并行PKP技術(shù)治療的病人,39例獲得隨訪,依據(jù)PKP術(shù)后是否應(yīng)用唑來膦酸治療,分成對照組及實(shí)驗(yàn)組。所有病人分別于術(shù)后第1天、術(shù)后半年、術(shù)后1年測量側(cè)位X光片上病椎及相鄰上下椎體的前緣及后緣高度,同時(shí)進(jìn)行VAS疼痛評分,評價(jià)治療效果。結(jié)果：PKP術(shù)后半年后對照組患者病椎及相鄰上下椎體前后緣高度顯著下降,年后這一下降趨勢更顯著。PKP聯(lián)合唑來膦酸治療6個(gè)月及12個(gè)月后,實(shí)驗(yàn)組患者病椎前后緣高度的丟失明顯低于對照組(P0.05)；聯(lián)合治療半年后,實(shí)驗(yàn)組中與病椎相鄰下椎體前緣高度丟失明顯低于對照組(P0.05),而兩組間下椎體后緣高度無顯著統(tǒng)計(jì)學(xué)差異(P0.05)。聯(lián)合治療并未減少上椎體前后緣高度的丟失(P0.05)。此外,實(shí)驗(yàn)組椎體疼痛癥狀較對照組緩解明顯,VAS評分較對照組低,治療后1年內(nèi)無新發(fā)骨折。結(jié)論：唑來膦酸聯(lián)合PKP治療老年椎體壓縮性骨折效果顯著,可明顯緩解術(shù)后病椎及相鄰椎體高度的丟失,并有效減輕全身及胸腰部骨性疼痛癥狀。應(yīng)用唑來膦酸給藥方便、依從性較好,不良反應(yīng)輕微、可達(dá)到全身系統(tǒng)化治療,可作為椎體壓縮性骨折PKP術(shù)后一種良好的輔助治療措施。
[Abstract]:Objective: to investigate the clinical effect of zoledronic acid combined with PKP in the treatment of senile vertebral compression fracture. Methods: 39 cases of senile vertebral compression fracture treated with PKP technique from 2012 to 2014 were analyzed retrospectively. According to whether zoledronic acid was used after PKP, they were divided into control group and experimental group. The anterior and posterior edge height of the diseased vertebrae and adjacent upper and lower vertebrae were measured on the first day, half a year and one year after operation respectively. The VAS pain score was also used to evaluate the therapeutic effect. Results the height of the anterior and posterior margins of the diseased vertebrae and adjacent upper and lower vertebrae in the control group decreased significantly half a year after the operation, especially after 6 and 12 months of treatment with PKP combined with zoledronic acid. The loss of anterior and posterior edge height of the patients in the experimental group was significantly lower than that of the control group (P 0.05), and the loss of the anterior height of the inferior vertebral body adjacent to the diseased vertebra in the experimental group was significantly lower than that of the control group after six months of combined treatment, but there was no significant difference between the two groups in the height of the posterior edge of the lower vertebral body. Combined therapy did not reduce the loss of anterior and posterior edge height of the upper vertebral body (P 0.05). In addition, the VAS score of the experimental group was significantly lower than that of the control group, and there were no new fractures within 1 year after treatment. Conclusion: Zoledronic acid combined with PKP is effective in the treatment of senile vertebral compression fractures. It can significantly relieve the loss of the height of the diseased vertebrae and adjacent vertebrae and alleviate the symptoms of systemic and thoracolumbar bone pain. Zoledronic acid can be used as a good adjuvant treatment after PKP for vertebral compression fracture.
【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R687.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 邱明才;骨質(zhì)疏松研究的現(xiàn)狀與展望[J];中華醫(yī)學(xué)雜志;2001年14期

，

本文編號：1862096